Stiripentol in Dravet Syndrome

Compassionate Use of Stiripentol in Intractable Epilepsy Due to Dravet Syndrome

Status

NO_LONGER_AVAILABLE

Phases

Unknown

Study type

Expanded Access

Source

ClinicalTrials.gov

Registry ID

NCT01533506

Enrollment

Unknown

Registered

2012-02-15

Start date

2012-02-29

Completion date

2013-02-28

Last updated

2013-02-28

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Dravet Syndrome

Keywords

treatment with stiripentol

Brief summary

The patient has failed all other available agents and has intractable epilepsy due to Dravet Syndrome. Stiripentol is highly efficacious in Dravet Syndrome. The overall goals of therapy with Stiripentol are primarily to significantly reduce the frequency and severity of seizures.

Interventions

DRUGstiripentol

Stiripentol up to 30 mg/kg/day to control seizures

Eligibility

Sex/Gender

FEMALE

Age

11 Years to No maximum

Healthy volunteers

Inclusion criteria

* Genetic diagnosis of Dravet syndrome with intractable seizures despite failing all available medications for seizures

Countries

United States

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026